Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 05, 2021

BUY
$90.24 - $124.05 $2.28 Million - $3.13 Million
25,215 Added 1254.48%
27,225 $308,000
Q2 2021

Aug 10, 2021

BUY
$93.66 - $139.27 $3,840 - $5,710
41 Added 2.08%
2,010 $250,000
Q1 2021

May 12, 2021

SELL
$116.57 - $155.01 $256,453 - $341,022
-2,200 Reduced 52.77%
1,969 $259,000
Q4 2020

Feb 11, 2021

SELL
$99.61 - $142.12 $138,557 - $197,688
-1,391 Reduced 25.02%
4,169 $549,000
Q3 2020

Nov 09, 2020

BUY
$72.92 - $102.01 $405,435 - $567,175
5,560 New
5,560 $567,000
Q1 2020

May 12, 2020

SELL
$37.9 - $104.44 $171,876 - $473,635
-4,535 Closed
0 $0
Q4 2019

Jan 28, 2020

BUY
$77.66 - $99.74 $107,559 - $138,139
1,385 Added 43.97%
4,535 $418,000
Q3 2019

Oct 22, 2019

BUY
$90.37 - $122.49 $119,740 - $162,299
1,325 Added 72.6%
3,150 $284,000
Q2 2019

Jul 18, 2019

SELL
$89.51 - $118.04 $158,880 - $209,521
-1,775 Reduced 49.31%
1,825 $215,000
Q1 2019

May 01, 2019

SELL
$61.98 - $96.5 $99,168 - $154,400
-1,600 Reduced 30.77%
3,600 $314,000
Q4 2018

Feb 13, 2019

SELL
$56.04 - $82.66 $11,208 - $16,532
-200 Reduced 3.7%
5,200 $328,000
Q3 2018

Nov 14, 2018

SELL
$48.29 - $80.6 $14,487 - $24,180
-300 Reduced 5.26%
5,400 $426,000
Q2 2018

Aug 14, 2018

BUY
$37.84 - $69.96 $215,688 - $398,771
5,700 New
5,700 $342,000
Q1 2018

May 18, 2018

SELL
$39.82 - $57.53 $179,229 - $258,942
-4,501 Closed
0 $0
Q4 2017

Feb 13, 2018

BUY
$46.49 - $60.51 $209,251 - $272,355
4,501
4,501 $237,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Moors & Cabot, Inc. Portfolio

Follow Moors & Cabot, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Moors & Cabot, Inc. with notifications on news.